Latest filing published 27 Feb 2026 for Avidity Biosciences, Inc..
No signal scores available.
Noreen Henig discloses dealings in Avidity Biosciences, Inc. to SEC (Form 4). Between 10 June 2025 and 27 February 2026, the trades on record add up to 2 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 27 February 2026, the filings show a transaction in Avidity Biosciences, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations